Lung Therapeutics's competitors

Lung Therapeutics's competitors include Amphastar Pharmaceuticals, E-Therapeutics, Adamas Pharmaceuticals and RespireRx Pharmaceuticals
Add company...
Lung Therapeutics
Lung Therapeutics pursues innovative treatments for underserved, life-threatening lung conditions.
Amphastar Pharmaceuticals
A specialty pharmaceutical company engaged in the development, manufacturing and marketing of generic and proprietary injectable and inhalation products.
E-Therapeutics
e-Therapeutics is a drug discovery and development company based in Oxford and Newcastle, UK. The Company is a pioneer of network pharmacology, a distinctive new approach to the discovery of medicines.
Adamas Pharmaceuticals
Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.
RespireRx Pharmaceuticals
RespireRx Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel drug therapies for the treatment of sleep apnea, drug-induced respiratory depression and other brain-mediated breathing disorders.
Founding Date
Founding Date
2013
Founding Date
1996
Founding Date
2003
Founding Date
2002
Founding Date
1988
Type
Type
Private
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Austin, US HQ
Locations
Rancho Cucamonga, US HQ
Locations
Long Hanborough, GB HQ
Locations
Emeryville, US HQ
Locations
Glen Rock, US HQ
Employees
Employees
10
Employees
1,541
Employees
24 11% decrease
Employees
84 15% increase
Employees
1
Valuation ($)
Valuation ($)
N/A
Valuation ($)
905.5 m
Valuation ($)
36.1 m
Valuation ($)
762.2 m
Valuation ($)
2.3 m
Facebook followers
Facebook followers
262
Facebook followers
76
Facebook followers
N/A
Facebook followers
N/A
Facebook followers
N/A

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$255.2m (FY, 2016)
Revenue (est.)
N/A
Revenue (est.)
$572k (FY, 2016)
Revenue (est.)
N/A
Net income
Net income
N/A
Net income
$10.5m (FY, 2016)
Net income
(£13.1m) (FY, 2017)
Net income
($60.1m) (FY, 2016)
Net income
($9.2m) (FY, 2016)
For sources of this data, please see the company profileDownload Excel

View company profiles